Payers use clinical drug compendia (NCCN, AHFS, Clinical Pharmacology, DrugDex, DrugPoints, Lexi Drugs) to classify drugs and biologics in formularies and to guide medical appropriateness of use. The compendia for Medicare and Medicaid are in federal law, while the compendia for commercial payers vary based on the states in which they operate and their own coverage rules. Commercial payers’ utilization of clinical drug compendia is not available in one place, making it difficult to understand the impact on patient access.

Avalere created the Payers’ Overarching Compendia Policies Dashboard to track off-label oncology coverage trends across the top 50 commercial payers, cumulatively covering over 160 million lives. The goal of this resource is to help manufacturers navigate coverage challenges and anticipate access barriers.

The dashboard identifies which compendia are referenced by plans, alignment with Centers for Medicare and Medicaid (CMS)-recognized sources, and how evidence ratings influence coverage. The dashboard includes trends in policies from 37 of the top 50 payers, representing 127 million covered lives.

Users can filter by compendium rating (e.g., National Comprehensive Cancer Network [NCCN] Category 2B) to assess coverage variations, supporting market access strategies, payer engagement, and denial analysis. Users can also filter by payer to see the evidence ratings the payer requires for coverage, which can support evidence generation/submission for denied claim appeals.

Most (74%) of payers mention one or more compendia in coverage policies. Among 37 payers with overarching policies, only three strictly follow CMS compendia and ratings, and four do not reference NCCN.  The Avalere dashboard also provides insights into geographic trends via an integrated heatmap, illustrating state-specific coverage.

Payer-specific interpretations of compendia create coverage disparities, leading to treatment delays. This dashboard helps stakeholders anticipate restrictions and understand evolving policies.

The Payers’ Overarching Compendia Policies Dashboard answers key questions, including:

• Which compendia are used for coverage decisions?
  • Differentiates between payers that adhere strictly to CMS-recognized sources versus those that apply additional internal review processes
  • Notes which compendia are cited most often
• How many lives are potentially impacted by compendia-driven decisions?
  • Estimates the number of covered lives affected by compendia
• How frequently are compendia referenced in policies?
  • Tracks types of compendia payers cite in policies
• Which commercial payers cover NCCN Category 2B?

Using this dashboard, manufacturers can optimize compendia inclusion, enhance payer engagement and market access strategy, and align data generation with coverage standards. Providers can use this dashboard to better understand payer-specific coverage complexities in advance of prescribing and when documenting information necessary for appeals, and to help minimize administrative burden.

As clinical drug compendia play a vital—yet inconsistently applied—role in coverage, this resource helps stakeholders advocate for fair evidence-based access, minimize disruptions, and improve timely patient access to innovative therapies.

This report is a key tool for reimbursement hotlines, and for provider and payer account managers, helping to navigate coverage denials. The policies in this report can also serve as a gap fill where payers do not have drug-specific coverage criteria.

Access The Report

Avalere’s experts in commercialization, regulatory, and policy strategy can help manufacturers, patient advocacy organizations, payers, and other stakeholders analyze the clinical coverage policies and access implications to off-label treatments and help develop strategies to mitigate delays in patient access to treatment.

To purchase the report or speak with an Avalere expert, contact Amy Schroeder at amy.schroeder@avalerehealth.com.